Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study

Overview

Journal Rheumatol Ther

Specialty Rehabilitation Medicine

Date 2024 Sep 17

PMID 39287897

Authors

Alan Kivitz

Jacques Eric Gottenberg

Martin Bergman

Chunfu Qiu

Hubert van Hoogstraten

Ron de Nijs

Louis Bessette

Affiliations

Soon will be listed here.

Abstract

Introduction: The 1-year PROspective sarilumab (preFILled syringe/pen) multinational, obsErvational (PROFILE) study evaluated the real-world effectiveness and safety of sarilumab in patients with moderate-to-severe rheumatoid arthritis (RA).

Methods: Safety endpoints included adverse events (AEs) and lab abnormalities. Effectiveness endpoints included the ACR core set. The primary endpoint was the change from baseline in Clinical Disease Activity Index (CDAI). All statistics are descriptive and p values were nominal.

Results: In total, 595 patients were treated, of whom 223 (37.5%) received sarilumab monotherapy and 372 (62.5%) received combination therapy. Upon initiation of sarilumab, an improvement in the mean (SD) CDAI score was observed at week 24 [11.4 (10.3)] and was maintained through week 52 [10.0 (10.5)], resulting in a mean [SD] reduction of -14.9 (12.7) and -14.4 (12.9), respectively. There were consistent improvements in disease activity that were similar for patients on monotherapy vs. combination therapy. An increase in the proportion of patients achieving remission and low disease activity was reported. By week 52, both groups had improved physical function and quality of life. There were no new safety signals. The proportions of any patients reporting a treatment-emergent adverse event (TEAE) or serious treatment-emergent AE (SAE) was 66.2% and 5.9%, respectively, and were similar between both treatment groups. Overall, 15.6% of patients discontinued sarilumab treatment due to TEAEs. The most commonly reported TEAE of interest was neutropenia (14.1%).

Conclusions: In this 1-year, observational real-world study, sarilumab therapy resulted in improved clinical outcomes. The safety profile was consistent with that observed in sarilumab randomized clinical trials. This study was entered on the German website (Paul Ehrlich Institute) on January 11, 2018, with NIS No.: 423.

References

Hennigan S, Kavanaugh A . Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2009; 4(4):767-75. PMC: 2621374. DOI: 10.2147/tcrm.s3470. View

Genovese M, Fleischmann R, Kivitz A, Rell-Bakalarska M, Martincova R, Fiore S . Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol. 2015; 67(6):1424-37. DOI: 10.1002/art.39093. View

Mankia K, Di Matteo A, Emery P . Prevention and cure: The major unmet needs in the management of rheumatoid arthritis. J Autoimmun. 2020; 110:102399. DOI: 10.1016/j.jaut.2019.102399. View

Burmester G, Bykerk V, Buch M, Tanaka Y, Kameda H, Praestgaard A . Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. Rheumatology (Oxford). 2021; 61(6):2596-2602. PMC: 9157062. DOI: 10.1093/rheumatology/keab676. View

Harrold L, Reed G, Best J, Zlotnick S, Kremer J . Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis. Rheumatol Ther. 2018; 5(2):507-523. PMC: 6251839. DOI: 10.1007/s40744-018-0127-1. View

Salvarani C, Cantini F, Niccoli L, Macchioni P, Consonni D, Bajocchi G . Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 2005; 53(1):33-8. DOI: 10.1002/art.20901. View

Emery P, Sebba A, Huizinga T . Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013; 72(12):1897-904. PMC: 3841743. DOI: 10.1136/annrheumdis-2013-203485. View

Kameda H, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham N . Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA). Mod Rheumatol. 2019; 30(2):239-248. DOI: 10.1080/14397595.2019.1639939. View

Favalli E . Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. Rheumatol Ther. 2020; 7(3):473-516. PMC: 7410942. DOI: 10.1007/s40744-020-00219-2. View

10.

Matcham F, Scott I, Rayner L, Hotopf M, Kingsley G, Norton S . The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014; 44(2):123-30. DOI: 10.1016/j.semarthrit.2014.05.001. View

11.

Backhaus M, Kaufmann J, Richter C, Wassenberg S, Roske A, Hellmann P . Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. Clin Rheumatol. 2015; 34(4):673-81. PMC: 4365186. DOI: 10.1007/s10067-015-2879-0. View

12.

Smolen J, Landewe R, Bijlsma J, Burmester G, Dougados M, Kerschbaumer A . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79(6):685-699. DOI: 10.1136/annrheumdis-2019-216655. View

13.

Bykerk V, Ostor A, Alvaro-Gracia J, Pavelka K, Ivorra J, Graninger W . Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clin Rheumatol. 2015; 34(3):563-71. PMC: 4348534. DOI: 10.1007/s10067-014-2857-y. View

14.

Dougados M, Kissel K, Sheeran T, Tak P, Conaghan P, Martin Mola E . Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2012; 72(1):43-50. PMC: 3551223. DOI: 10.1136/annrheumdis-2011-201282. View

15.

Johnston S, McMorrow D, Farr A, Juneau P, Ogale S . Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic. Rheumatol Ther. 2016; 2(1):59-71. PMC: 4883249. DOI: 10.1007/s40744-014-0006-3. View

16.

Pappas D, Blachley T, Zlotnick S, Best J, Emeanuru K, Kremer J . Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry. Rheumatol Ther. 2020; 7(2):357-369. PMC: 7211217. DOI: 10.1007/s40744-020-00200-z. View

17.

van der Geest K, Abdulahad W, Rutgers A, Horst G, Bijzet J, Arends S . Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology (Oxford). 2015; 54(8):1397-402. DOI: 10.1093/rheumatology/keu526. View

18.

Gu T, Mutebi A, Stolshek B, Tan H . Cost of biologic treatment persistence or switching in rheumatoid arthritis. Am J Manag Care. 2018; 24(8 Spec No.):SP338-SP345. View

19.

Blonde L, Khunti K, Harris S, Meizinger C, Skolnik N . Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv Ther. 2018; 35(11):1763-1774. PMC: 6223979. DOI: 10.1007/s12325-018-0805-y. View

20.

Hochberg M, Chang R, Dwosh I, Lindsey S, Pincus T, Wolfe F . The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992; 35(5):498-502. DOI: 10.1002/art.1780350502. View